Brief: Molecure Signs Deal For Phase II Clinical Trial Of OATD-01
03/07/2023 16:20
July 3 (Reuters) - Molecure SA MOCP.WA :
* SIGNS DEAL FOR PROOF-OF-CONCEPT TYPE OF PHASE II CLINICAL
TRIAL
OF OATD-01
* DEAL SIGNED WITH FRENCH ORION SANTE SARL
Source text for Eikon: ID:nEM4dXVDca
Further company coverage: MOCP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Molecure SA
See all newsBrief: Molecure Q1 Net Loss 4.1 Mln Zlotys
Brief: Molecure Says Its In-Consortium Project Selected For Funding By Medical Research Agency
Brief: Molecure To Sell 4.12 Mln Series K Shares and 2.0 Mln Existing Shares At 5 Zlotys/Shr
Brief: Molecure Starts ABB For Up to 4.12 Mln New Series K Shares And Up To 2.0 Mln Existing Shares
Brief: Molecure Signs Conditional Investment Agreement With MS Galleon And Szumowski Investments